Search clinical trials for: Dapagliflozin 10 MG

Total 12666 results

National Institute of Cardiology, Warsaw, Poland
Amsterdam UMC, location VUmc; University of Eastern Finland; Medical University...

Recruiting

Empagliflozin in Hypertrophic Cardiomyopathy (EMPA-REPAIR)

Heart Failure | Hypertrophic Cardiomyopathy

Poland
NHS Greater Glasgow and Clyde
University of Glasgow

Active, not recruiting

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)

Myocardial Infarction

United Kingdom
Centre Hospitalier Universitaire Vaudois

Completed

Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN)

Nephropathy

Switzerland
Assiut University

Not yet recruiting

SGLT2 Inhibitors and Perioperative Period

Perioperative Complication
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boehringer...

Recruiting

Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)

End Stage Renal Disease

United States
LG Chem

Not yet recruiting

Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

Healthy Volunteers
Shanghai Zhongshan Hospital

Active, not recruiting

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial) (READ)

Type 2 Diabetes

China
Sohag University

Not yet recruiting

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Fatty Liver, Nonalcoholic
October 6 University
University of Florida; Beni-Suef University; National Heart Institute, Egypt

Recruiting

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Heart Failure | Genetic Polymorphisms

United States
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
China National Center for Cardiovascular Diseases

Recruiting

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Hypertension | Pre-Heart Failure

China
Yale University
Boehringer Ingelheim

Recruiting

Empagliflozin in Patients With Cirrhosis and Ascites (EMPA Liver)

Liver Failure | Cirrhosis

United States
University Medical Center Groningen

Completed

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE)

Heart Failure; With Decompensation | Heart Failure，Congestive | Heart Failure Acute

Netherlands
Singapore General Hospital
Duke-NUS Graduate Medical School

Terminated

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) ((MEDiaN))

Diabetic Nephropathies

Singapore
NHS Greater Glasgow and Clyde
University of Glasgow

Completed

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects (SUGAR-DM-HF)

Heart Failure | Diabetes Mellitus

United Kingdom
Ohio State University Comprehensive Cancer Center
Schwartz, Steven, PhD

Completed

Prostate Biomarkers in Men Consuming Tomato Products

Prostate Cancer

United States
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Medical University of Vienna
Attoquant Diagnostics

Completed

EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3

Austria
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Netherlands, Japan, Italy, Denmark, Israel, Canada, France, India, Germany
University of California, San Diego
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Type 1 Diabetes

United States
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Brazil
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
NHS Greater Glasgow and Clyde
University of Glasgow

Active, not recruiting

DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance (DAPARESIST)

Heart Failure

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Healthy

Belgium
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Type 2 Diabetes Mellitus
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Kiyuk Chang
Seoul St. Mary's Hospital; Pusan National University Hospital; Korea University... and other collaborators

Recruiting

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study (RECORD-AMI)

Myocardial Infarction | Diabetes Mellitus, Type 2

Korea, Republic of
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Vanderbilt University Medical Center
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF)

Heart Failure | Diabetes Mellitus, Type 2

United States
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 (MERCURI-2)

Acute Kidney Injury | Cardiac Surgery | Sodium-Glucose Transporter 2 Inhibitor

Netherlands
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
Centro Universitario de Ciencias de la Salud, Mexico

Unknown

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
University of Leicester
AstraZeneca; Royal Surrey County Hospital NHS Foundation Trust

Completed

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes (SINGLED)

Type 2 Diabetes

United Kingdom
LG Chem

Unknown

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

T2DM
The University of Hong Kong

Recruiting

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) (CATCH-EM)

Type 2 Diabetes | Microvascular Coronary Artery Disease

Hong Kong
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
University of Catanzaro

Completed

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (FIORE)

Type 2 Diabetes | Cardiovascular Risk Factor

Italy
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States

Search clinical trials for: Dapagliflozin 10 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations